Provided by Tiger Fintech (Singapore) Pte. Ltd.

Century Therapeutics, Inc.

0.5437
+0.04378.74%
Post-market: 0.5350-0.0087-1.60%19:42 EDT
Volume:657.55K
Turnover:353.10K
Market Cap:46.78M
PE:-0.34
High:0.5572
Open:0.5000
Low:0.5000
Close:0.5000
Loading ...

Century Therapeutics Inc : H.c. Wainwright Cuts Target Price to $2 From $5

THOMSON REUTERS
·
03 Apr

Century Therapeutics price target lowered to $2 from $5 at H.C. Wainwright

TIPRANKS
·
03 Apr

Century Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $2 From $5

THOMSON REUTERS
·
03 Apr

Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC) and Lexeo Therapeutics, Inc. (LXEO)

TIPRANKS
·
25 Mar

Century Therapeutics price target lowered to $7 from $11 at Chardan

TIPRANKS
·
24 Mar

Chardan Cuts Price Target on Century Therapeutics to $7 From $11, Keeps Buy Rating

MT Newswires Live
·
24 Mar

Century Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
21 Mar

Century Therapeutics Inc : Guggenheim Cuts Target Price to $5 From $12

THOMSON REUTERS
·
21 Mar

Century Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
21 Mar

Century Therapeutics Inc : Leerink Partners Cuts Target Price to $8 From $13

THOMSON REUTERS
·
20 Mar

Century Therapeutics price target lowered to $2 from $4 at Piper Sandler

TIPRANKS
·
20 Mar

William Blair Sticks to Their Hold Rating for Century Therapeutics (IPSC)

TIPRANKS
·
20 Mar

Century Therapeutics (IPSC) Receives a Buy from Piper Sandler

TIPRANKS
·
20 Mar

Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
20 Mar

Century Therapeutics trading halted, news pending

TIPRANKS
·
20 Mar

Century Therapeutics FY24 EPS $(1.61) Up From $(2.30) YoY; Revenue $6.59M Up From $2.24M YoY

Benzinga
·
20 Mar

Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

THOMSON REUTERS
·
20 Mar

Press Release: Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Dow Jones
·
20 Mar

BRIEF-Century Therapeutics Receives Nasdaq Notice For Bid Price Deficiency

Reuters
·
01 Mar

Leerink Partners Remains a Buy on Century Therapeutics (IPSC)

TIPRANKS
·
14 Feb